Nektar Therapeutics Files 8-K

TL;DR

Nektar filed an 8-K on Nov 8, 2025. Details to follow.

AI Summary

Nektar Therapeutics filed an 8-K on November 10, 2025, reporting events as of November 8, 2025. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits. No specific financial figures or material events were detailed in the provided text snippet.

Why It Matters

This 8-K filing indicates Nektar Therapeutics is providing updates to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial data that would indicate a high-risk situation.

Key Players & Entities

• Nektar Therapeutics (company) — Registrant
• November 8, 2025 (date) — Date of earliest event reported
• November 10, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke

Filing Documents

• ea0264736-8k_nektar.htm (8-K) — 30KB
• ea026473601ex99-1_nektar.htm (EX-99.1) — 29KB
• ex99-1_001.jpg (GRAPHIC) — 3KB
• ex99-1_002.jpg (GRAPHIC) — 1KB
• 0001213900-25-107821.txt ( ) — 236KB
• nktr-20251108.xsd (EX-101.SCH) — 3KB
• nktr-20251108_lab.xml (EX-101.LAB) — 33KB
• nktr-20251108_pre.xml (EX-101.PRE) — 22KB
• ea0264736-8k_nektar_htm.xml (XML) — 3KB

01 Regulation FD

Item 7.01 Regulation FD. On November 8, 2025, Nektar Therapeutics (the "Company") issued a press release reporting new data from its ongoing Phase 2b REZOLVE-AD (atopic dermatitis) clinical trial. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

01 Other Events

Item 8.01 Other Events. On November 8, 2025, new data from the Company's ongoing Phase 2b REZOLVE-AD trial was presented in a late-breaking oral session at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. The Company's Phase 2b REZOLVE-AD trial enrolled 393 patients with moderate-to-severe atopic dermatitis, of which 99 also reported having a history of asthma with ACQ-5 data available at both baseline and week 16. A pre-planned analysis in the trial evaluated scores from a validated Asthma Control Questionnaire (ACQ-5) at baseline and at the end of a 16-week induction period. For these patients reporting a history of asthma, all three rezpegaldesleukin doses demonstrated an overall reduction in mean observed ACQ-5 scores at week 16 with two dose arms (24 g/kg q2w and 24 g/kg q4w) achieving statistical significance (p<0.05) as compared to placebo. Patients in the placebo arm reported an overall worsening of mean ACQ-5 scores. In patients who had a baseline ACQ-5 score of 0.5 or higher (n=53), at least half of the patients experienced clinically significant improvement in their ACQ-5 score across all treatment arms, compared to 13% in the placebo arm. Among the 25 patients with uncontrolled asthma at baseline (1.5 ACQ-5 score), all three active doses of rezpegaldesleukin demonstrated a meaningful improvement in mean observed ACQ-5 scores at week 16 and all dose arms achieved statistical significance (p<0.05) as compared to placebo. Placebo-adjusted reductions of mean ACQ-5 score in this subset of patients with uncontrolled asthma at baseline ranged from 1.0 to 1.4. In addition, data was presented for a total of 42 placebo patients who crossed over at week 16 and continued in the study on a treatment escape arm to receive high dose rezpegaldesleukin (24 g/kg q2w). Based on observed data from these patients with data at crossover week 24: EASI-75 response rate was 60% (n=30); vIGA-AD 0/1 response rate was 33% (n=30); EAS

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release titled "New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: November 10, 2025 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2

View Full Filing

View this 8-K filing on SEC EDGAR